For example, an mRNA cancer vaccine named “autogene cevumeran” encoding up to 20 neoantigens, developed by BioNTech, is used in combination with atelozolizumab (an anti-PDL1 antibody), and a chemotherapy regimen comprising four drugs (folinic acid, fluorouracil, irinotecan, and oxaliplatin, also called mFOLFIRINOX), and was assessed in a phase 1 clinical trial on patients with resected pancreatic ductal adenocarcinoma (PDAC). The gene discussed is CD274; the disease is cancer.